RBC Capital Maintains Outperform on Repligen, Lowers Price Target to $200
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Conor McNamara has maintained an 'Outperform' rating on Repligen (NASDAQ:RGEN) but lowered the price target from $207 to $200.
November 01, 2023 | 4:52 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Repligen's price target has been lowered from $207 to $200 by RBC Capital, though the 'Outperform' rating is maintained.
The lowering of the price target by RBC Capital could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential upside, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100